InspireMD Inc (NSPR) Q3 2025 Earnings Top Estimates, Fueled by Strong Sales Beat InspireMD (NSPR) Q3 2025 results beat revenue estimates by 40%, driven by the successful U.S. launch of its CGuard Prime carotid stent system.
Unusual volume stocks are being observed in Wednesday's session. The trading volume of these stocks is deviating from the norm in today's session.
Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (
NYSE:KOS ) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic The company’s revenue increased marginally to $1.52 million, driven by the continued adoption of its CGuard technology in existing markets.
NSPR Stock Earnings: InspireMD Misses EPS, Misses Revenue for Q2 2024 NSPR stock results show that InspireMD missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
NSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024 NSPR stock results show that InspireMD missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023 NSPR stock results show that InspireMD beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Earnings Scheduled For March 6, 2024 Companies Reporting Before The Bell • CTS (
NYSE:CTS ) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
